Search

Your search keyword '"Ellemunter, H."' showing total 284 results
Start Over Author "Ellemunter, H."
284 results on '"Ellemunter, H."'

3. 293 Impact of elexacaftor-tezacaftor-ivacaftor on lung function, nutritional status, pulmonary exacerbation, and sweat chloride in people with cystic fibrosis: real-world evidence from German Cystic Fibrosis Registry

Author

Sutharsan, S., primary, Dillenhöfer, S., additional, Welsner, M., additional, Stehling, F., additional, Brinkmann, F., additional, Burkhart, M., additional, Ellemunter, H., additional, Dittrich, A., additional, Smaczny, C., additional, Eickmeier, O., additional, Kappler, M., additional, Schwarz, C., additional, Sieber, S., additional, Naehrig, S., additional, and Naehrlich, L., additional

Published
2023
Full Text
View/download PDF

8. Diagnose der Mukoviszidose (S2)

Author

NÄHRLICH, L., primary, STUHRMANN-SPANGENBERG, M., additional, BARBEN, J., additional, BARGON, J., additional, BLANKENSTEIN, O., additional, BREMER, W., additional, BRUNSMANN, F., additional, BUCHHOLZ, T., additional, ELLEMUNTER, H., additional, FUSCH, C., additional, GEMBRUCH, U., additional, HAMMERMANN, J., additional, JACOBEIT, J., additional, JUNG, A., additional, KEIM, V., additional, KOPP, I., additional, LOFF, S., additional, MAYR, S., additional, PFEIFFER-AULER, S., additional, ROSSI, R., additional, SITTER, H., additional, STERN, M., additional, STRASSBURG, C., additional, and DERICHS, N., additional

Published
2015
Full Text
View/download PDF

9. Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis

Author

Hanafin, PO, Sermet-Gaudelus, I, Griese, M, Kappler, M, Ellemunter, H, Schwarz, C, Wilson, J, Tan, M, Velkov, T, Rao, GG, Schneider-Futschik, EK, Hanafin, PO, Sermet-Gaudelus, I, Griese, M, Kappler, M, Ellemunter, H, Schwarz, C, Wilson, J, Tan, M, Velkov, T, Rao, GG, and Schneider-Futschik, EK

Abstract

Background: The advent of cystic fibrosis transmembrane conductance regulator protein (CFTR) modulators like ivacaftor have revolutionised the treatment of cystic fibrosis (CF). However, due to the plethora of variances in disease manifestations in CF, there are inherent challenges in unified responses under CFTR modulator treatment arising from variability in patient outcomes. The pharmacokinetic (PK) data available for ivacaftor-lumacaftor cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator drug combination is limited. Methods: Secondary objectives were to identify (1) patient characteristics and (2) the interactions between ivacaftor-lumacaftor responsible for interindividual variability (IIV). Results: Peak plasma concentrations (Cmax) of ivacaftor - lumacaftor were >10 fold lower than expected compared to label information. The one-way ANOVA indicated that the patient site had an effect on Cmax values of ivacaftor metabolites ivacaftor-M1, ivacaftor-M6, and lumacaftor (p < 0.001, p < 0.001, and p < 0.001, respectively). The Spearman's rho test indicated that patient weight and age have an effect on the Cmax of lumacaftor (p = 0.003 and p < 0.001, respectively) and ivacaftor metabolite M1 (p = 0.020 and p < 0.001, respectively). Age (p < 0.001) was found to effect on Cmax of ivacaftor M6 and on Tmax of ivacaftor M1 (p = 0.026). A large impact of patient characteristics on the IIV of PK parameters Cmax and Tmax, was observed among the CF patients. Conclusion: Understanding the many sources of variability can help reduce this individual patient variability and ensure consistent patient outcomes.

Published
2021

13. MOLECULAR ANALYSIS OF STAPHYLOCOCCUS AUREUS ISOLATES FROM AN ONGOING PROSPECTIVE OBSERVATIONAL LONGITUDINAL MULTICENTER STUDY DETERMINING STAPHYLOCOCCUS AUREUS AIRWAY COLONIZATION OR INFECTION IN CYSTIC FIBROSIS PATIENTS: 307

Author

Braun, N., Duebbers, A., Kuester, P., Ellemunter, H., Heuer, E., Sextro, W., Junge, S., Tuemmler, B., Mellies, U., Teschler, H., Mainz, J. G., Riethmueller, J., Graepler-Mainka, U., Koerner-Rettberg, C., Ballmann, M., Szczepanski, R., Wald, A., Wisbauer, M., Adelsberger, D., Staab, D., Wollschläger, B., Hammermann, J., Peters, G., Becker, K., and Kahl, B. C.

Published
2011

26. S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Modul 2: Diagnostik und Therapie bei der chronischen Infektion mit Pseudomonas aeruginosa

Author

Schwarz, C., additional, Schulte-Hubbert, B., additional, Bend, J., additional, Abele-Horn, M., additional, Baumann, I., additional, Bremer, W., additional, Brunsmann, F., additional, Dieninghoff, D., additional, Eickmeier, O., additional, Ellemunter, H., additional, Fischer, R., additional, Grosse-Onnebrink, J., additional, Hammermann, J., additional, Hebestreit, H., additional, Hogardt, M., additional, Hügel, C., additional, Hug, M., additional, Illing, S., additional, Jung, A., additional, Kahl, B., additional, Koitschev, A., additional, Mahlberg, R., additional, Mainz, J., additional, Mattner, F., additional, Mehl, A., additional, Möller, A., additional, Muche-Borowski, C., additional, Nüßlein, T., additional, Puderbach, M., additional, Renner, S., additional, Rietschel, E., additional, Ringshausen, F., additional, Schmidt, S., additional, Sedlacek, L., additional, Sitter, H., additional, Smaczny, C., additional, Tümmler, B., additional, Vonberg, R., additional, Wielpütz, M., additional, Wilkens, H., additional, Wollschläger, B., additional, Zerlik, J., additional, Düesberg, U., additional, and van Koningsbruggen-Rietschel, S., additional

Published
2018
Full Text
View/download PDF

27. CF Lung Disease - a German S3 Guideline: Module 2: Diagnostics and Treatment in Chronic Infection with Pseudomonas aeruginosa

Author

Schwarz, C., Schulte-Hubbert, B., Bend, J., Abele-Horn, M., Baumann, I., Bremer, W., Brunsmann, F., Dieninghoff, D., Eickmeier, O., Ellemunter, H., Fischer, R., Grosse-Onnebrink, J., Hammermann, J., Hebestreit, H., Hogardt, M., Huegel, C., Hug, M., Illing, S., Jung, A., Kahl, B., Koitschev, A., Mahlberg, R., Mainz, J. G., Mattner, F., Mehl, A., Moeller, A., Muche-Borowski, C., Nuesslein, T., Puderbach, M., Renner, S., Rietschel, E., Ringshausen, F. C., Schmidt, S., Sedlacek, L., Sitter, H., Smaczny, C., Tuemmler, B., Vonberg, R., Wielpuetz, M. O., Wilkens, H., Wollschlaeger, B., Zerlik, J., Dueesberg, U., van Koningsbruggen-Rietschel, S., Schwarz, C., Schulte-Hubbert, B., Bend, J., Abele-Horn, M., Baumann, I., Bremer, W., Brunsmann, F., Dieninghoff, D., Eickmeier, O., Ellemunter, H., Fischer, R., Grosse-Onnebrink, J., Hammermann, J., Hebestreit, H., Hogardt, M., Huegel, C., Hug, M., Illing, S., Jung, A., Kahl, B., Koitschev, A., Mahlberg, R., Mainz, J. G., Mattner, F., Mehl, A., Moeller, A., Muche-Borowski, C., Nuesslein, T., Puderbach, M., Renner, S., Rietschel, E., Ringshausen, F. C., Schmidt, S., Sedlacek, L., Sitter, H., Smaczny, C., Tuemmler, B., Vonberg, R., Wielpuetz, M. O., Wilkens, H., Wollschlaeger, B., Zerlik, J., Dueesberg, U., and van Koningsbruggen-Rietschel, S.

Abstract

Cystic Fibrosis (CF) is the most common autosomal-recessive genetic disease affecting approximately 8000 people in Germany. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leading to dysfunction of CFTR, a transmembrane chloride channel. This defect causes insufficient hydration of the epithelial lining fluid which leads to chronic inflammation of the airways. Recurrent infections of the airways as well as pulmonary exacerbations aggravate chronic inflammation, lead to pulmonary fibrosis and tissue destruction up to global respiratory insufficiency, which is responsible for the mortality in over 90% of patients. The main aim of pulmonary treatment in CF is to reduce pulmonary inflammation and chronic infection. Pseudomonas aeruginosa ( Pa ) is the most relevant pathogen in the course of CF lung disease. Colonization and chronic infection are leading to additional loss of pulmonary function. There are many possibilities to treat Pa -infection. This is a S3-clinical guideline which implements a definition for chronic Pa -infection and demonstrates evidence-based diagnostic methods and medical treatment for Pa -infection in order to give guidance for individual treatment options.

Published
2018

32. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis

Author

Iannitti, R.G., Napolioni, V., Oikonomou, V., Luca, A. De, Galosi, C., Pariano, M., Massi-Benedetti, C., Borghi, M., Puccetti, M., Lucidi, V., Colombo, C., Fiscarelli, E., Lass-Florl, C., Majo, F., Cariani, L., Russo, M., Porcaro, L., Ricciotti, G., Ellemunter, H., Ratclif, L., Benedictis, F.M. De, Talesa, V.N., Dinarello, C.A., Veerdonk, F.L. van de, Romani, L., Iannitti, R.G., Napolioni, V., Oikonomou, V., Luca, A. De, Galosi, C., Pariano, M., Massi-Benedetti, C., Borghi, M., Puccetti, M., Lucidi, V., Colombo, C., Fiscarelli, E., Lass-Florl, C., Majo, F., Cariani, L., Russo, M., Porcaro, L., Ricciotti, G., Ellemunter, H., Ratclif, L., Benedictis, F.M. De, Talesa, V.N., Dinarello, C.A., Veerdonk, F.L. van de, and Romani, L.

Abstract

Contains fulltext : 172723.pdf (publisher's version ) (Open Access), Dysregulated inflammasome activation contributes to respiratory infections and pathologic airway inflammation. Through basic and translational approaches involving murine models and human genetic epidemiology, we show here the importance of the different inflammasomes in regulating inflammatory responses in mice and humans with cystic fibrosis (CF), a life-threatening disorder of the lungs and digestive system. While both contributing to pathogen clearance, NLRP3 more than NLRC4 contributes to deleterious inflammatory responses in CF and correlates with defective NLRC4-dependent IL-1Ra production. Disease susceptibility in mice and microbial colonization in humans occurrs in conditions of genetic deficiency of NLRC4 or IL-1Ra and can be rescued by administration of the recombinant IL-1Ra, anakinra. These results indicate that pathogenic NLRP3 activity in CF could be negatively regulated by IL-1Ra and provide a proof-of-concept evidence that inflammasomes are potential targets to limit the pathological consequences of microbial colonization in CF.

Published
2016

33. Factors associated with worse lung function in cystic fibrosis patients with persistent staphylococcus aureus

Author

Junge, S. (Sibylle), Görlich, D. (Dennis), Reijer, M.D. (Martijn Den), Wiedemann, B. (Baerbel), Tümmler, B. (Burkhard), Ellemunter, H., Dübbers, A. (Angelika), Küster, P. (Peter), Ballmann, M., Koerner-Rettberg, C. (Cordula), Große-Onnebrink, J. (Jörg), Heuer, E. (Eberhardt), Sextro, W. (Wolfgang), Mainz, J.G. (Jochen G.), Hammermann, J. (Jutta), Riethmüller, J. (Joachim), Graepler-Mainka, U.M. (Ute M.), Staab, D. (Doris), Wollschläger, B. (Bettina), Szczepanski, R. (Rüdiger), Schuster, A. (Antje), Tegtmeyer, F.-K. (Friedrich-Karl), Sutharsan, S. (Sivagurunathan), Wald, A. (Alexandra), Nofer, J.-R. (Jerzy-Roch), Wamel, W.J.B. (Willem) van, Becker, K. (Karsten), Peters, G. (Georg), Kahl, B.C. (Barbara C.), Junge, S. (Sibylle), Görlich, D. (Dennis), Reijer, M.D. (Martijn Den), Wiedemann, B. (Baerbel), Tümmler, B. (Burkhard), Ellemunter, H., Dübbers, A. (Angelika), Küster, P. (Peter), Ballmann, M., Koerner-Rettberg, C. (Cordula), Große-Onnebrink, J. (Jörg), Heuer, E. (Eberhardt), Sextro, W. (Wolfgang), Mainz, J.G. (Jochen G.), Hammermann, J. (Jutta), Riethmüller, J. (Joachim), Graepler-Mainka, U.M. (Ute M.), Staab, D. (Doris), Wollschläger, B. (Bettina), Szczepanski, R. (Rüdiger), Schuster, A. (Antje), Tegtmeyer, F.-K. (Friedrich-Karl), Sutharsan, S. (Sivagurunathan), Wald, A. (Alexandra), Nofer, J.-R. (Jerzy-Roch), Wamel, W.J.B. (Willem) van, Becker, K. (Karsten), Peters, G. (Georg), and Kahl, B.C. (Barbara C.)

Abstract

Background Staphylococcus aureus is an important pathogen in cystic fibrosis (CF). However, it is not clear which factors are associated with worse lung function in patients with persistent S. aureus airway cultures. Our main hypothesis was that patients with high S. aureus density in their respiratory specimens would more likely experience worsening of their lung disease than patients with low bacterial loads. Methods Therefore, we conducted an observational prospective longitudinal multi-center study and assessed the association between lung function and S. aureus bacterial density in respiratory samples, co-infection with other CF-pathogens, nasal S. aureus carriage, clinical status, antibiotic therapy, IL-6- and IgG-levels against S. aureus virulence factors. Results 195 patients from 17 centers were followed; each patient had an average of 7 visits. Data were analyzed using descriptive statistics and generalized linear mixed models. Our main hypothesis was only supported for patients providing throat specimens indicating that patients with higher density experienced a steeper lung function decline (p<0.001). Patients with exacerbations (n = 60), S. aureus small-colony variants (SCVs, n = 84) and co-infection with Stenotrophomonas maltophilia (n = 44) had worse lung function (p = 0.0068; p = 0.0011; p = 0.0103). Patients with SCVs were older (p = 0.0066) and more often treated with trimethoprim/sulfamethoxazole (p = 0.0078). IL-6 levels positively correlated with decreased lung function (p<0.001), S. aureus density in sputa (p = 0.0016), SCVs (p = 0.0209), exacerbations (p = 0.0041) and co-infections with S. maltophilia (p = 0.0195) or A. fumigatus (p = 0.0496). Conclusions In CF-patients with chronic S. aureus cultures, independent risk factors for worse lung function are high bacterial density in throat cultures, exacerbations, elevated IL-6 levels, presence of S. aureus SCVs and co-infection with S. maltophilia.

Published
2016
Full Text
View/download PDF

34. Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus

Author

Junge, S, Gorlich, D, Reijer, Martijn, Wiedemann, B, Tummler, B, Ellemunter, H, Dubbers, A, Kuster, P, Ballmann, M, Koerner-Rettberg, C, Grosse-Onnebrink, J, Heuer, E, Sextro, W, Mainz, J G, Hammermann, J, Riethmuller, J, Graepler-Mainka, U, Staab, D, Wollschlager, B, Szczepanski, R, Schuster, A, Tegtmeyer, F K, Sutharsan, S, Wald, A, Nofer, J R, van Wamel, Willem, Becker, K, Peters, G, Kahl, B C, Junge, S, Gorlich, D, Reijer, Martijn, Wiedemann, B, Tummler, B, Ellemunter, H, Dubbers, A, Kuster, P, Ballmann, M, Koerner-Rettberg, C, Grosse-Onnebrink, J, Heuer, E, Sextro, W, Mainz, J G, Hammermann, J, Riethmuller, J, Graepler-Mainka, U, Staab, D, Wollschlager, B, Szczepanski, R, Schuster, A, Tegtmeyer, F K, Sutharsan, S, Wald, A, Nofer, J R, van Wamel, Willem, Becker, K, Peters, G, and Kahl, B C

Published
2016

36. Practical Guidelines: Lung Transplantation in Patients with Cystic Fibrosis

Author

Hirche, T. O., Knoop, C., Hebestreit, H., Shimmin, D., Solé, A., Elborn, J. S., Ellemunter, H., Aurora, P., Hogardt, M., Wagner, T. O. F., and ECORN-CF Study Group

Subjects
Article Subject
Abstract

There are no European recommendations on issues specifically related to lung transplantation (LTX) in cystic fibrosis (CF). The main goal of this paper is to provide CF care team members with clinically relevant CF-specific information on all aspects of LTX, highlighting areas of consensus and controversy throughout Europe. Bilateral lung transplantation has been shown to be an important therapeutic option for end-stage CF pulmonary disease. Transplant function and patient survival after transplantation are better than in most other indications for this procedure. Attention though has to be paid to pretransplant morbidity, time for referral, evaluation, indication, and contraindication in children and in adults. This review makes extensive use of specific evidence in the field of lung transplantation in CF patients and addresses all issues of practical importance. The requirements of pre-, peri-, and postoperative management are discussed in detail including bridging to transplant and postoperative complications, immune suppression, chronic allograft dysfunction, infection, and malignancies being the most important. Among the contributors to this guiding information are 19 members of the ECORN-CF project and other experts. The document is endorsed by the European Cystic Fibrosis Society and sponsored by the Christiane Herzog Foundation.

Published
2014
Full Text
View/download PDF

37. S2-Konsensus-Leitlinie 'Diagnose der Mukoviszidose'

Author

Naehrlich, L, Stuhrmann-Spangenberg, M, Barben, J, Bargoni, J, Blankenstein, O, Bremern, W, Brunsmann, F, Ellemunter, H, Fusch, C, Gembruch, U, Hammermann, J, Jacobeit, J, Jung, A, and University of Zurich

Subjects
10036 Medical Clinic, 610 Medicine & health
Published
2013

45. WS19.9 A prospective multicenter study to dissect Staphylococcus aureus-colonization from infection in cystic fibrosis patients

Author

Junge, S., primary, Wiedemann, B., additional, Tümmler, B., additional, Dübbers, A., additional, Küster, P., additional, Nofer, J., additional, Ellemunter, H., additional, Mainz, J.G., additional, Heuer, E., additional, Sextro, W., additional, Körner-Rettberg, C., additional, Ballmann, M., additional, Mellies, U., additional, Hammermann, J., additional, Teschler, H., additional, Szczepanski, R., additional, Tegtmeyer, F.K., additional, Graepler-Mainka, U., additional, Riethmueller, J., additional, Wald, A., additional, Wollschläger, B., additional, Staab, D., additional, Schuster, A., additional, Becker, K., additional, Peters, G., additional, and Kahl, B.C., additional

Published
2013
Full Text
View/download PDF

50. PEDIATRIC LIVER TRANSPLANTATION - THE INNSBRUCK EXPERIENCE

Author

Öllinger, R., primary, Margreiter, C., additional, Biebl, M., additional, Müller, T., additional, Schneeberger, S., additional, Sucher, R., additional, Ellemunter, H., additional, Mark, W., additional, Margreiter, R., additional, and Pratschke, J., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results